Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.36 |
| ▸ | BACE1 | P56817 | 5/20 | 0.36 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.36 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.36 |
| ▸ | MME | P08473 | 2/20 | 0.35 |
| ▸ | GNPAT | O15228 | 1/20 | 0.34 |
| ▸ | CTSD | P07339 | 1/20 | 0.34 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.33 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30792485 | 0.84 | PDCD1LG2 (0.42) | OPRD1PTPN1BACE1PDCD1LG2CD274 | |
| SCHEMBL2223562 | 0.83 | MME (0.40) | PTPN1BACE1MMEGNPATCTSD | |
| SCHEMBL2184922 | 0.82 | DPP4 (0.47) | PTPN1BACE1CTSDBACE2DPP4 | |
| SCHEMBL2196474 | 0.82 | DPP4 (0.47) | PTPN1BACE1CTSDBACE2DPP4 | |
| SCHEMBL1035791 | 0.82 | CTSC (0.40) | PDCD1LG2CD274DPP4DPP8DPP9 | |
| SCHEMBL29630580 | 0.81 | MME (0.48) | PDCD1LG2CD274MMEGNPAT | |
| SCHEMBL29658865 | 0.81 | MME (0.48) | PDCD1LG2CD274MMEGNPAT | |
| SCHEMBL30564978 | 0.81 | MME (0.44) | BACE1PDCD1LG2CD274MMEGNPAT | |
| SCHEMBL29630462 | 0.80 | MME (0.48) | BACE1PDCD1LG2CD274MMEGNPAT | |
| SCHEMBL16468562 | 0.80 | DPP4 (0.47) | BACE1GNPATCTSDBACE2DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110166063-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NEKTAR THERAPEUTICS (US) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166063-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NGLY1, CD44, IAPP | OPRD1 3100/4885PTPN1 2074/4885BACE1 2543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.